ALX OncologyALXO
ALXO
About: ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Employees: 80
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
124% more call options, than puts
Call options by funds: $427K | Put options by funds: $191K
55% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
7% less funds holding
Funds holding: 92 [Q3] → 86 (-6) [Q4]
8.54% less ownership
Funds ownership: 86.39% [Q3] → 77.85% (-8.54%) [Q4]
17% less capital invested
Capital invested by funds: $83.2M [Q3] → $68.9M (-$14.3M) [Q4]
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1.50
74%
upside
Avg. target
$4.14
381%
upside
High target
$9
947%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Stifel Bradley Canino 14% 1-year accuracy 4 / 29 met price target | 74%upside $1.50 | Hold Maintained | 7 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 23% 1-year accuracy 45 / 199 met price target | 481%upside $5 | Buy Reiterated | 7 Mar 2025 |
Piper Sandler Christopher Raymond 30% 1-year accuracy 9 / 30 met price target | 947%upside $9 | Overweight Maintained | 6 Mar 2025 |
Jefferies Michael Yee 27% 1-year accuracy 3 / 11 met price target | 249%upside $3 | Buy Upgraded | 6 Mar 2025 |
UBS Colin Bristow 27% 1-year accuracy 4 / 15 met price target | 156%upside $2.20 | Buy Maintained | 27 Jan 2025 |
Financial journalist opinion
Based on 4 articles about ALXO published over the past 30 days
Neutral
GlobeNewsWire
6 days ago
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI
Neutral
GlobeNewsWire
1 week ago
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancers Advancing novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, into clinical-stage development with IND submission planned for Q1 2025 Company implements strategic prioritization, resource optimizations and reductions to extend cash runway into Q4 2026 Webcast featuring company leadership and external key opinion leaders to take place today at 6:00 a.m. PT/9:00 a.m.
Neutral
GlobeNewsWire
2 weeks ago
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.
Neutral
GlobeNewsWire
3 weeks ago
ALX Oncology to Host Virtual R&D Day on March 5, 2025
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m.
Neutral
GlobeNewsWire
1 month ago
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, announced positive updated data from the ASPEN-06 Phase 2 clinical trial demonstrating that the company's investigational CD47-blocker evorpacept generates a durable clinical response with a well-tolerated safety profile among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The updated results, which build upon previously announced topline results, will be shared today in an oral presentation (Abstract #332) at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco.
Neutral
GlobeNewsWire
1 month ago
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that effective January 21, 2025, the Compensation Committee of the Board of Directors of ALX Oncology granted an inducement stock option to purchase a total of 600,000 shares of ALX Oncology's common stock to Harish Shantharam, the Company's Chief Financial Officer, in connection with the commencement of his employment. Mr. Shantharam's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and were granted as inducements material to Mr. Shantharam to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the company will host a virtual event on Thursday, January 23, at 1:00 p.m. PT/4:00 p.m. ET to discuss updated data from the ASPEN-06 Phase 2 clinical trial evaluating the company's investigational CD47-blocker evorpacept in patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.
Positive
Zacks Investment Research
2 months ago
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Here is how ALX Oncology Holdings Inc. (ALXO) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
2 months ago
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 - 25, 2025.
Negative
Zacks Investment Research
3 months ago
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ALX Oncology Holdings (ALXO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Charts implemented using Lightweight Charts™